Abstract
Interleukin-23 is currently considered one of the main cytokines involved in the pathogenesis of psoriasis. In relation to this knowledge, IL-23 inhibitors guselkumab, tildrakizumab and risankizumab have been introduced into the treatment of psoriasis.
The individual IL-23 inhibitors differ slightly in terms of their characteristics, pharmacodynamics and pharmacokinetics, and certain differences can also be found with regard to their efficacy and safety profile - the results of indirect comparisons in meta-analyses suggest that risankizumab has the highest efficacy of all IL-23 inhibitors. The use of risankizumab in first-line treatment os psoriasis can lead to a rapid archievement of clear/almost clear skin in a lrage proportion of patients and to a significant improvement in their quality of life, and thereby prevent the cumulative life course impairment due to psoriasis.